Comparison of Brain-derived Neurotrophic Factor Level in Depressed Patients Treated with Fluoxetine and Sertraline

Sonny Teddy Lisal; Nur Aeni M. A. Fattah; Rahmawati Nur Indah; Saidah Syamsuddin

doi:10.3889/oamjms.2021.6348

Authors

Sonny Teddy Lisal Department of Psychiatry, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Nur Aeni M. A. Fattah Department of Psychiatry, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Rahmawati Nur Indah Department of Psychiatry, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Saidah Syamsuddin Department of Psychiatry, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2021.6348

Keywords:

Fluoxetine, Sertraline, Hamilton depression rating scale, Brain-derived neurotrophic factor, Depression

Abstract

Background: The Brain-Derived NeurotrophicFactor (BDNF) is the main neuronal growth factor in the brain that regulates neurogenesis, neuronal maturity, synaptic formation and plasticity. Studies showed BDNF level decreased in depression and the administration of anti depressant drugs increased BDNF level. In this study, we used fluoxetine and sertraline, which are Selective Serotonin Reuptake Inhibitor (SSRI) but had a different mechanism in influencing the BDNF levels. The purpose of this study was to compare the effect of fluoxetine and sertraline administration tothe BDNF level in depressed subjects. This study was conducted at Wahidin Sudirohusodo Hospital, Makassar, Indonesia and its affiliates from January to February 2019. Twenty outpatient subjects were diagnosed with depression based on DSM-V. The subjects were either antidepressant naïve, or dropping out of antidepressant therapy for at least 3 months since the last administration. Blood samples from each subject were taken by consecutive sampling, and BDNF levels were analyzed before and after administration of fluoxetine and sertraline for six weeks. Also, Hamilton Depression Rating Scale (HDRS) scores are measured before and after administration. The BDNF serum was significantly increased by 100.6% (p<0,001) from the baseline level in the fluoxetine group and 75.4% in the sertraline group. HDRS score was decreased by39.5% (p<0,001) in the fluoxetine group and 30.1% in the sertraline group after six weeks of administration. This study suggests that fluoxetine was superior to sertraline in increasing the BDNF level in depression.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Kusumawardhani, et al. Guide to Major Depression Disorders. PDSKJI; 2013.

Nurmiati A. Depression of the Aspects of Neurology, Diagnosis and Management. Jakarta: University of Indonesia Medical School; 2005.

Ministry of Health of the Republic of Indonesia. The Role of Families Supports Community Mental Health. Indonesia: Ministry of Health of the Republic of Indonesia; 2016. p. 1-2. https://doi.org/10.18311/jeoh/2020/26134 DOI: https://doi.org/10.18311/jeoh/2020/26134

Afrilia S. 9 Million People in Indonesia Experience Depression; 2017. Available from: https://www.gaya.tempo.co. [Last accessed on 2021 May 10].

Li G, Jing P, Liu Z, Li Z, Ma H, Tu W, et al. The beneficial effect of fluoxetine treatment against psychological stress is mediated by increasing BDNF expression in selected brain areas. Oncotarget. 2017;8(41):69527-37. https://doi.org/10.18632/oncotarget.17891 PMid:29050222 DOI: https://doi.org/10.18632/oncotarget.17891

Francesco M, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L, et al. Change in BDNF serum level in patients with major depression disorder (MDD) after a 6 month treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res. 2009;43(3):247-54. https://doi.org/10.1016/j. jpsychires.2008.03.014 PMid:18511076 DOI: https://doi.org/10.1016/j.jpsychires.2008.03.014

Ayse DB, Yazici K, Aslan E, Delialioğlu N, Taşdelen B, Acar ST, et al. Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients. 2009;33(2):281-5. https://doi.org/10.1016/j.pnpbp.2008.11.016 PMid:19110026 DOI: https://doi.org/10.1016/j.pnpbp.2008.11.016

Scabia G, Barone I, Mainardi M, Ceccarini G, Scali M, Buzzigoli E, et al. The Antidepressant Fluoxetine Acts On Energy Balance and Leptin sensitivity Via BDNF. Sci Rep. 2018;8:1781. https://doi.org/10.1038/s41598-018-19886-x DOI: https://doi.org/10.1038/s41598-018-19886-x

Sylvia DE, et al. Psychiatric Textbook. 2nd ed. Indonesia: Medical Faculty, University of Indonesia; 2013.

Stahl SM. Stahl’s Essential Psychopharmacology. 4th ed. New York: Cambridge University Press; 2013.

Stahl SM. Antipsychotic Agents in Stahl’s Essential Psychopharmacology. 3rd ed. New York: Cambridge University Press; 2008. p. 336-41.

Kazuko S. Brain-Derived Neurotrophic Factor For Depression Therapeutic; 2014. p. 1-10. Available from: http://www.oustinpublishgroup.org. [Last accessed on 2021 May 10].

Raffaela M, Calabrese F, Bedogni F, Tongiorgi E, Fumagalli F, Racagni G, et al. Chronic treatment with fluoxetine up-regulates cellular BDNF mRNA experiment in rat Dopaminergic Region. Int J Neuropsychopharmacol. 2006;9(3):307-17. https://doi.org/10.1017/s1461145705005766 PMid:16035958 DOI: https://doi.org/10.1017/S1461145705005766

Halaris A, Sharma A, Meresh E, Pandey G, Kang R, Hage B, et al. BDNF serum: A potential biomarker for major depressive disorder and antidepressant response prediction. J Depress Anxiety. 2015;4:1-8. https://doi.org/10.4172/2167-1044.1000179 DOI: https://doi.org/10.4172/2167-1044.1000179

Phillips C. Brain-derived neurotrophic factor, depression, and physical activity; making the neuroplastic connection. Neural Plast. 2017;2017:7260130. https://doi.org/10.1155/2017/7260130 PMid:28928987 DOI: https://doi.org/10.1155/2017/7260130

Bun-Hee L, Kim YK. The poles of BDNF in the pathophysiology of major depression Psychiatry Investig. 2010;7(4):231-5. PMid:21253405 DOI: https://doi.org/10.4306/pi.2010.7.4.231

Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, et al. Blood BDNF concentration reflect brain-tissue. BDNF level. Int J Neuropsychopharmacol. 2011;14(3):347-53. https://doi.org/10.1017/s1461145710000738 PMid:20604989 DOI: https://doi.org/10.1017/S1461145710000738

Björkholm C, Monteggia LM. BDNF-a Key Transducer of antidepressant effects. Neuropharmacology. 2016;102:72-9. https://doi.org/10.1016/j.neuropharm.2015.10.034 PMid:26519901 DOI: https://doi.org/10.1016/j.neuropharm.2015.10.034

Owen M, Wolf J, Shelly W, Rosser R, Burke HM, Lerner GK, et al. Serum BDNF level before treatment predict SSRI response in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1623-30. https://doi.org/10.1016/j.pnpbp.2011.06.013 PMid:21749907 DOI: https://doi.org/10.1016/j.pnpbp.2011.06.013

SidneyH, Gorwood P. Successful Management of major Depressive Disorder. 2nd ed. France; 2014.

Arumugam V, John VS, Augustine N, Jacob T, Joy SM, Sen S, et al. The impact of antidepressant treatment on brain-derived neurotrophic factor level: An evidence-based approach through systemic review and meta-analysis. Indian J Pharmacol. 2017;49(3):236-42. https://doi.org/10.4103/ijp.ijp_700_16 PMid:29033483 DOI: https://doi.org/10.4103/ijp.IJP_700_16